Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eszopiclone

FDA-approved product (tablet, oral), marketed as Eszopiclone, Lunesta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Eszopiclone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine related drugs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eszopiclone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eszopiclone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

    NCT01102270 · start 2009-01

    Registered record
    Registry ID
    NCT01102270
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-05
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionEszopiclone; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?

    NCT00811746 · start 2008-12

    Registered record
    Registry ID
    NCT00811746
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Rozerem (Ramelteon); Lunesta (Eszopiclone); Historical Controls
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-12
    Completion
    2010-10
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionRozerem (Ramelteon); Lunesta (Eszopiclone); Historical Controls
    PhaseNot applicable
    Registry statusCompleted

  • A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)

    NCT00770692 · start 2008-10

    Registered record
    Registry ID
    NCT00770692
    Conditions
    Insomnia
    Interventions
    Eszopiclone 1 mg- Elderly; Eszopiclone 2 mg- Elderly; Eszopiclone 3 mg- Non-elderly; Eszopiclone 2 mg- Non-elderly
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-10
    Completion
    2010-05
    Enrolment
    369

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionEszopiclone 1 mg- Elderly; Eszopiclone 2 mg- Elderly; Eszopiclone 3 mg- Non-elderly; Eszopiclone 2 mg- Non-elderly
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

    NCT00893269 · start 2008-10

    Registered record
    Registry ID
    NCT00893269
    Conditions
    Marijuana Dependence
    Interventions
    eszopiclone; Placebo; ramelteon; zolpidem
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2010-10
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMarijuana Dependence
    Interventioneszopiclone; Placebo; ramelteon; zolpidem
    PhasePhase 1
    Registry statusCompleted

  • A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)

    NCT00770510 · start 2008-09

    Registered record
    Registry ID
    NCT00770510
    Conditions
    Primary Insomnia
    Interventions
    Eszopiclone 1 mg; Eszopiclone 2 mg; Eszopiclone 3 mg; Placebo; Zolpidem Tartrate 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2008-09
    Completion
    2010-05
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insomnia
    InterventionEszopiclone 1 mg; Eszopiclone 2 mg; Eszopiclone 3 mg; Placebo +1 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fasting Conditions

    NCT02322645 · start 2008-08

    Registered record
    Registry ID
    NCT02322645
    Conditions
    Healthy
    Interventions
    Eszopiclone Tablets 3 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08
    Completion
    2008-10
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEszopiclone Tablets 3 mg
    PhasePhase 1
    Registry statusCompleted

  • An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.

    NCT00699608 · start 2008-07

    Registered record
    Registry ID
    NCT00699608
    Conditions
    Healthy Subjects; Sleep Initiation and Maintenance Disorders
    Interventions
    GSK1755165; placebo; zopiclone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2008-10
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects; Sleep Initiation and Maintenance Disorders
    InterventionGSK1755165; placebo; zopiclone
    PhasePhase 3
    Registry statusCompleted

  • Brain Mechanisms and Targeting Insomnia in Major Depression

    NCT00628914 · start 2008-05

    Registered record
    Registry ID
    NCT00628914
    Conditions
    Major Depressive Disorder; Insomnia
    Interventions
    escitalopram and eszopiclone; Escitalopram, eszopiclone, and placebo; Escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-05
    Completion
    2010-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Insomnia
    Interventionescitalopram and eszopiclone; Escitalopram, eszopiclone, and placebo; Escitalopram
    PhasePhase 4
    Registry statusUnknown

  • Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia

    NCT00645944 · start 2008-04

    Registered record
    Registry ID
    NCT00645944
    Conditions
    Insomnia; Schizophrenia; Schizoaffective Disorder; Sleep Disorders
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-04
    Completion
    2011-04
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Schizophrenia; Schizoaffective Disorder; Sleep Disorders
    InterventionEszopiclone; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Treatment of Insomnia and Glucose Metabolism

    NCT00724282 · start 2008-04

    Registered record
    Registry ID
    NCT00724282
    Conditions
    Sleep; Insomnia; Insulin Resistance
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-04
    Completion
    2012-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep; Insomnia; Insulin Resistance
    InterventionEszopiclone; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects

    NCT00616655 · start 2008-01

    Registered record
    Registry ID
    NCT00616655
    Conditions
    Generalized Anxiety Disorder
    Interventions
    eszopiclone; eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-12
    Enrolment
    456

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    Interventioneszopiclone; eszopiclone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome

    NCT00822679 · start 2007-10

    Registered record
    Registry ID
    NCT00822679
    Conditions
    Acute Coronary Syndrome; Sleep Disorder
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-10
    Completion
    2010-01
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Sleep Disorder
    InterventionEszopiclone; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

    NCT00511134 · start 2007-04

    Registered record
    Registry ID
    NCT00511134
    Conditions
    Insomnia; Nicotine Dependence
    Interventions
    Eszopiclone; Bupropion
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-04
    Completion
    2008-12
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Nicotine Dependence
    InterventionEszopiclone; Bupropion
    PhasePhase 4
    Registry statusTerminated

  • Ezopiclone Improves the Quality of Overnight Polysomnography

    NCT00507117 · start 2007-03

    Registered record
    Registry ID
    NCT00507117
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Lunesta; Placebo control
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-03
    Completion
    2007-10
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionLunesta; Placebo control
    PhasePhase 4
    Registry statusCompleted

  • How do Sleeping Pills Affect Pain in the Brain?

    NCT00414037 · start 2006-12

    Registered record
    Registry ID
    NCT00414037
    Conditions
    Primary Insomnia
    Interventions
    Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2006-12
    Completion
    2008-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insomnia
    InterventionEszopiclone; Placebo
    PhasePhase 4
    Registry statusTerminated